Gilead Sciences, Inc. $GILD Position Increased by Fifth Third Bancorp

Fifth Third Bancorp raised its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 0.7% during the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 724,639 shares of the biopharmaceutical company’s stock after acquiring an additional 5,215 shares during the quarter. Fifth Third Bancorp owned approximately 0.06% of Gilead Sciences worth $108,008,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of GILD. Maryland State Retirement & Pension System boosted its stake in shares of Gilead Sciences by 12.5% during the 3rd quarter. Maryland State Retirement & Pension System now owns 75,589 shares of the biopharmaceutical company’s stock worth $11,267,000 after acquiring an additional 8,393 shares during the last quarter. UNIVEST FINANCIAL Corp bought a new stake in shares of Gilead Sciences during the 3rd quarter valued at $275,000. Joel Isaacson & Co. LLC increased its stake in shares of Gilead Sciences by 12.3% in the 3rd quarter. Joel Isaacson & Co. LLC now owns 1,938 shares of the biopharmaceutical company’s stock worth $289,000 after purchasing an additional 213 shares in the last quarter. Valued Wealth Advisors LLC increased its stake in shares of Gilead Sciences by 14.1% in the 3rd quarter. Valued Wealth Advisors LLC now owns 744 shares of the biopharmaceutical company’s stock worth $111,000 after purchasing an additional 92 shares in the last quarter. Finally, First Command Advisory Services Inc. increased its stake in shares of Gilead Sciences by 124.9% in the 3rd quarter. First Command Advisory Services Inc. now owns 704 shares of the biopharmaceutical company’s stock worth $105,000 after purchasing an additional 391 shares in the last quarter. Institutional investors own 83.67% of the company’s stock.

More Gilead Sciences News

These are some of the GILD news items that stood out recently:

• Positive Sentiment: Gilead reported PURPOSE 5 results showing twice-yearly injectable lenacapavir outperformed daily oral HIV prevention on persistence, with no HIV infections in the injectable group. The findings could strengthen the long-term opportunity for its HIV prevention franchise. Gilead Sciences Posts PURPOSE 5 Win As HIV Shot Beats Daily Pills
• Neutral Sentiment: Valuation views are mixed after GILD’s substantial multi-year advance: one analysis sees the shares as undervalued based on cash-flow potential, while another considers them fully valued after the rally. This may make further gains more dependent on continued execution. Gilead Stock Still Looks Undervalued On Its 205% Run Gilead Looks Fully Valued
• Neutral Sentiment: Gilead partner Xilio expects to provide Gilead with an option data package for efarindodekin alfa in the first half of 2027. This is a potential pipeline catalyst, but remains several months away and is dependent on future data. Xilio Therapeutics Pipeline Update

Insider Activity at Gilead Sciences

In other news, CEO Daniel O’Day sold 9,810 shares of the firm’s stock in a transaction dated Thursday, November 5th. The stock was sold at an average price of $175.17, for a total transaction of $1,718,417.70. Following the completion of the transaction, the chief executive officer owned 551,683 shares in the company, valued at $96,638,311.11. This trade represents a 1.75% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Wettan Keeley M. Cain sold 3,399 shares of Gilead Sciences stock in a transaction dated Friday, November 6th. The stock was sold at an average price of $164.11, for a total value of $557,809.89. Following the completion of the sale, the executive vice president directly owned 5,360 shares in the company, valued at $879,629.60. This trade represents a 38.81% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 242,709 shares of company stock worth $39,503,427 in the last quarter. 0.30% of the stock is owned by company insiders.

Analysts Set New Price Targets

GILD has been the topic of a number of recent research reports. Needham & Company LLC set a $175.00 target price on Gilead Sciences in a report on Friday, October 30th. Barclays cut their price target on Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating for the company in a report on Wednesday, July 29th. UBS Group boosted their price target on Gilead Sciences from $175.00 to $195.00 and gave the company a “buy” rating in a report on Friday, October 30th. TD Cowen upped their price target on Gilead Sciences from $160.00 to $175.00 and gave the stock a “buy” rating in a research report on Friday, October 30th. Finally, Zacks Research downgraded Gilead Sciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 29th. Twenty-three investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat, Gilead Sciences currently has an average rating of “Moderate Buy” and an average target price of $170.15.

Gilead Sciences Trading Down 0.7%

Shares of GILD opened at $169.73 on Thursday. The firm has a market cap of $210.52 billion, a P/E ratio of -53.71 and a beta of 0.35. The company has a debt-to-equity ratio of 1.84, a current ratio of 1.38 and a quick ratio of 1.22. Gilead Sciences, Inc. has a 1 year low of $116.88 and a 1 year high of $176.58. The company has a 50 day simple moving average of $154.40 and a two-hundred day simple moving average of $141.51.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 EPS for the quarter, topping the consensus estimate of $2.19 by $0.36. Gilead Sciences had a negative net margin of 12.47% and a negative return on equity of 1.85%. The firm had revenue of $8.30 billion for the quarter, compared to the consensus estimate of $7.81 billion. During the same quarter in the previous year, the firm earned $2.47 earnings per share. The company’s quarterly revenue was up 6.8% compared to the same quarter last year. On average, equities analysts expect that Gilead Sciences, Inc. will post -0.98 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, December 30th. Shareholders of record on Tuesday, December 15th will be paid a $0.82 dividend. The ex-dividend date is Tuesday, December 15th. This represents a $3.28 annualized dividend and a yield of 1.9%. Gilead Sciences’s payout ratio is presently -103.80%.

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes medicines for serious diseases. Founded in 1987 and headquartered in Foster City, California, the company focuses on antiviral therapies, including treatments and preventive medicines for HIV and medicines for viral hepatitis. Its products include Biktarvy for HIV and Epclusa for hepatitis C. Gilead also develops medicines in areas such as oncology and inflammatory diseases. Its portfolio includes Veklury (remdesivir), an antiviral medicine used to treat COVID-19.